Sagalowsky AI - Search Results

1

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM Jr; SWOG S1011 Trial Investigators. Lerner SP, et al. Among authors: sagalowsky ai. N Engl J Med. 2024 Oct 3;391(13):1206-1216. doi: 10.1056/NEJMoa2401497. N Engl J Med. 2024. PMID: 39589370 Free PMC article. Clinical Trial.

2

Is extended lymphadenectomy of beneficial therapeutic value for T2 urothelial cancer?

Skinner EC, Sagalowsky AI. Skinner EC, et al. Among authors: sagalowsky ai. J Urol. 2014 May;191(5):1206-8. doi: 10.1016/j.juro.2014.02.040. Epub 2014 Feb 20. J Urol. 2014. PMID: 24560793 No abstract available.

3

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Among authors: sagalowsky ai. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

4

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Among authors: sagalowsky ai. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

5

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Among authors: sagalowsky ai. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

6

The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma.

Svatek RS, Lotan Y, Herman MP, Duchene DA, Sagalowsky AI, Cadeddu JA. Svatek RS, et al. Among authors: sagalowsky ai. J Urol. 2006 Oct;176(4 Pt 1):1321-5; discussion 125. doi: 10.1016/j.juro.2006.06.008. J Urol. 2006. PMID: 16952621

7

Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy.

Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Shariat SF, et al. Among authors: sagalowsky ai. Urology. 2006 Sep;68(3):538-42. doi: 10.1016/j.urology.2006.03.033. Epub 2006 Sep 18. Urology. 2006. PMID: 16979748

8

Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.

Abdel-Aziz KF, Anderson JK, Svatek R, Margulis V, Sagalowsky AI, Cadeddu JA. Abdel-Aziz KF, et al. Among authors: sagalowsky ai. J Endourol. 2006 Sep;20(9):627-31. doi: 10.1089/end.2006.20.627. J Endourol. 2006. PMID: 16999613

9

Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.

Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Margulis V, et al. Among authors: sagalowsky ai. Clin Cancer Res. 2006 Dec 15;12(24):7369-73. doi: 10.1158/1078-0432.CCR-06-1472. Clin Cancer Res. 2006. PMID: 17189409

10

Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.

Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y. Margulis V, et al. Among authors: sagalowsky ai. J Urol. 2007 Mar;177(3):1163-8. doi: 10.1016/j.juro.2006.10.033. J Urol. 2007. PMID: 17296438

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters